Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/s10434-007-9574-6
Annals of Surgical Oncology 14:3412-3418 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mansour, J. C.
Right arrow Articles by Coit, D. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mansour, J. C.
Right arrow Articles by Coit, D. G.

Original Article

Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer?

John C. Mansour, MD1, Laura Tang, MD1, Manish Shah, MD1, David Bentrem, MD2, David S. Klimstra, MD1, Mithat Gonen, PhD1, David P. Kelsen, MD1, Murray F. Brennan, MD1 and Daniel G. Coit, MD1

1 Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
2 Northwestern University, Evanston, IL, USA

Correspondence: Address correspondence and reprint requests to: Daniel G. Coit, MD; E-mail: coitd{at}mskcc.org

Background: After publication of the MAGIC trial results, preoperative chemotherapy is increasingly used to treat advanced gastric cancer before resection. Tools for measuring response must be assessed.

Methods: We identified all patients with gastric cancer treated with neoadjuvant chemotherapy and R0 resection between 1991 and 2005 from a prospective database. Patients receiving preoperative radiation were excluded. Histologic response to treatment was graded from 0% to 100% by a single pathologist. Kaplan-Meier survival analysis was performed to identify the relationship between response and outcome and to identify factors predictive of disease-specific survival (DSS). Multivariate analysis was performed to identify independent predictors.

Results: A total of 168 patients underwent R0 resection after receiving neoadjuvant chemotherapy. Thirty-three percent of tumors were at the gastroesophageal junction. Cisplatin-based therapy was used for 68% of patients. Twenty-two percent of patients had a >50% pathologic response to treatment. Median follow-up after resection for all patients was 25 months. Median DSS for all patients was 33 months. Three-year DSS improved from 44% to 69% with at least a 50% histologic response (P = .01). Factors associated with decreased DSS included positive nodes at resection, pT3 tumor or greater, high grade, perineural or vascular invasion, and <50% response. Multivariate analysis identified nodal status and perineural or vascular invasion as independent predictors of survival.

Conclusions: Posttreatment nodal status and perineural or vascular invasion at resection, but not graded histologic response, independently predict DSS after neoadjuvant chemotherapy and surgical resection of gastric cancer.

Key Words: Gastric cancer • Pathologic response • Chemotherapy • Neoadjuvant • Graded histologic response




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
J. C. Mansour and D. G. Coit
Appropriate Treatment for Patients with Gastric Adenocarcinoma
Ann. Surg. Oncol., June 1, 2008; 15(6): 1798 - 1799.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.